Thoughts on Afrezza Direct Purchase Program

MannKind recently announced a new direct purchase program for Afrezza, offering the drug for as little as $4/day for the first 1000 patients who sign up for the program through http://www.insulinsavings.com. Additionally, MannKind said it is launching an enhanced $15 copay card program; however, the copay card website does not appear to have been updated as of yet. Below, FENIX provides thoughts on the Afrezza program, an RAI pricing analysis, and insight how the program may help drive payer coverage. Afrezza direct purchase program details The Afrezza direct purchase program allows the first 1000 patients a $120 introductory price for 90……

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.